Amino acid decarboxylases are a class of enzymes that catalyze the removal of the carboxyl group from specific amino acids to produce biologically active amines. These enzymes are widely involved in various physiological processes, particularly in the synthesis of neurotransmitters and polyamines. Aromatic L-amino acid decarboxylase (AADC), histidine decarboxylase (HDC), and S-adenosylmethionine decarboxylase (SAMDC) all belong to the amino acid decarboxylase family, each playing an important role in different metabolic pathways to regulate cellular functions.
AADC is primarily responsible for converting aromatic amino acid precursors l-DOPA and 5-hydroxytryptophan into the neurotransmitters dopamine and serotonin. These neurotransmitters are crucial for the normal functioning of the brain, and AADC deficiency leads to severe neurological disorders, including motor dysfunction, autonomic nervous system dysfunction, and behavioral abnormalities.
HDC catalyzes the conversion of histidine to histamine. Histamine is an important mediator in allergic and inflammatory reactions, and a deficiency in HDC is closely related to immune dysfunction and allergic symptoms. For example, in some chronic inflammation and allergic reactions, the upregulation of HDC plays a crucial role in regulating histamine levels and immune cell function.
SAMDC is a key enzyme in the polyamine biosynthetic pathway, responsible for converting S-adenosylmethionine into decarboxylated S-adenosylmethionine, a precursor for the synthesis of spermidine and spermine. These polyamines play vital roles in cell growth, differentiation, and proliferation. The activity of SAMDC is closely related to the cellular concentration of polyamines, and SAMDC inhibitors are widely studied for anticancer and antiparasitic treatments.
Inhibitors targeting amino acid decarboxylases have potential applications in cancer and parasitic disease research. For example, since the polyamine biosynthetic pathway is upregulated in many tumors, SAMDC inhibitors can be used in cancer research, and SAMDC inhibitors are also important tools in antiparasitic research[1][2][3][4].
(Z)-Aconitic acid 是一种口服活性的谷氨酸脱羧酶 (glutamate decarboxylase) 抑制剂,可降低 IκB-α 磷酸化,并抑制抗原诱发的关节炎和 Monosodium urate (MS-E13881) 诱发的痛风。
L-Allylglycine(L-2-Allylglycine)是一种氨基酸衍生物,作为谷氨酸脱羧酶(glutamate decarboxylase,GAD)的抑制剂,可降低脑内 GABA 的生物合成,并具有致惊厥活性。
L-Allylglycine (L-2-Allylglycine) hydrochloride 是一种氨基酸衍生物,作为谷氨酸脱羧酶 (glutamate decarboxylase (GAD)) 的抑制剂,可降低脑内 GABA 的生物合成,并具有致惊厥活性。
Qc1 (Standard) 是 Qc1 (MS-K43749) 的分析标准品,可用于研究及分析应用,作为一种苏氨酸脱氢酶 (TDH) 抑制剂,Qc1 可用于研究代谢性疾病。
α-Fluoromethylhistidine dihydrochloride 是一种口服有效的组氨酸脱羧酶抑制剂,可清除肠嗜铬样 (ECL) 细胞中的组胺,减少 ECL 细胞中分泌囊泡的数量和体积密度,但不影响肥大细胞的组胺储存,可消除 Omeprazole (MS-S71685) 诱导的 ECL 细胞空泡形成并减少胃泌素 (gastrin) 诱发的 ECL 细胞组胺外流,同时不会改变 ECL 细胞的颗粒特性、Omeprazole 诱导的 ECL 细胞肥大、胃泌素诱发的胰抑素样免疫反应性外流,也不会影响组胺或迷走神经刺激引起的胃酸分泌,此外还能抑制基础和胃泌素刺激的胃酸分泌,降低胃泌素+IBMX (MS-X84938) 诱导的酸输出量,但不会直接影响分离壁细胞的酸生成。
α-FMH (α-Fluoromethylhistidine) 是一种口服有效的组氨酸脱羧酶 (histidine decarboxylase) 抑制剂,可清除肠嗜铬样 (ECL) 细胞中的组胺,减少 ECL 细胞中分泌囊泡的数量和体积密度,但不影响肥大细胞的组胺储存,可消除 Omeprazole (MS-S71685) 诱导的 ECL 细胞空泡形成,并减少胃泌素 (gastrin) 诱发的 ECL 细胞组胺外流,同时不会改变 ECL 细胞的颗粒特性、Omeprazole 诱导的 ECL 细胞肥大、胃泌素诱发的胰抑素样免疫反应性外流,也不会影响组胺或迷走神经刺激引起的胃酸分泌,此外还能抑制基础和胃泌素刺激的胃酸分泌,降低胃泌素+IBMX (MS-X84938) 诱导的酸输出量,但不会直接影响分离壁细胞的酸生成。
Chelidamic acid 是一种含吡喃骨架的杂环有机酸,具有良好的金属离子配位能力,同时也是最有效的谷氨酸脱羧酶 (glutamate decarboxylase) 抑制剂之一,其 Ki 值为 33 μM。
© 2026 MolStrong. 保留所有权利。粤ICP备2023004355号
可通过CAS号进行批量搜索,一行一个CAS号